BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence (AI) to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, focuses on immuno-oncology treatments. The company’s proprietary AI platform, NovareAI, enables the identification of new therapeutic indications by analyzing existing approved drugs and clinically validated product candidates. This approach aims to reduce development costs and accelerate timelines, thereby increasing the likelihood of clinical and regulatory success.

BioXcel Therapeutics’ innovative use of AI in drug re-innovation allows for the rapid advancement of treatments. For instance, the company developed IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, moving from first-in-human trials to FDA approval in less than four years. This strategy addresses the challenges of traditional drug development by repurposing existing compounds for new therapeutic uses, thereby potentially reducing the time and cost associated with bringing new treatments to market.

In the realm of AI, BioXcel Therapeutics operates within the category of drug repurposing and development. By employing AI-driven methodologies, the company efficiently identifies and develops new therapeutic indications for existing drugs, streamlining the drug development process and addressing unmet medical needs.

For more information, please visit bioxceltherapeutics.com.

To claim this startup page, go to the Contact page and send us a message with your full name, startup name, job title, and startup email address. We will review your request and get back to you. Once verified, you can update your startup information.